DE10220458A1 - Treating respiratory diseases, e.g. bronchitis or asthma, using combination of proton pump inhibitor, e.g. omeprazole, and conventional respiratory therapeutic agent, e.g. cilomilast - Google Patents

Abstract

A medicament for treating respiratory diseases contains a proton pump inhibitor (I) and a respiratory therapeutic agent (II) in a fixed or free combination (specifically a fixed oral combination). Independent claims are also included for: (1) a method for treating respiratory diseases, involving administration of an effective amount of (I) together with (II); (2) the use of (I) in combination with (II) for treating respiratory disease patients; (3) a pharmaceutical preparation for treating respiratory diseases, containing (I) and (II) as active agents; and (4) ready-for-use medicaments, comprising (I) and (II) for simultaneous or successive administration, successive administration being immediate or after a longer delay.

Description

Technical field

The invention relates to the combination of certain known active ingredients for therapeutic purposes.

State of the art

A whole series of compounds are known from the prior art, the Inhibit gastric acid secretion by blocking the proton pump and therefore also as Proton pump inhibitors (PPI) are called. These compounds are suitable for Treatment of gastrointestinal disorders and reflux esophagitis, and some of them are approved by the health authorities in this regard. Furthermore, are from the prior art Known compounds that can be used to treat respiratory diseases and hereinafter referred to as respiratory therapies. Your combined application in The inventive sense for therapeutic purposes has not yet been described in the prior art.

Description of the invention

Surprisingly, it has now been found that the proton pump inhibitors, their original Area of application is the treatment of gastric and intestinal diseases, in a special way are used in combination with respiratory therapies for the treatment of respiratory diseases to be used.

The invention thus relates in a first aspect to the combined use of Proton pump inhibitors and respiratory therapies in the treatment of respiratory diseases.

Proton pump inhibitors are substances that are blocked by Proton pump inhibit gastric acid secretion, that is, to the H + / K + -ATPase, that for the Enzyme responsible for gastric acid secretion, bind covalently. These primarily include active ingredients with 2 - [(2- Pyridinyl) methylsulfinyl] -1H-benzimidazole basic structure, or with related basic structures, wherein these basic structures can be substituted in many different ways. From the concept According to the invention, "proton pump inhibitors" are not only the active substances as such, but also theirs includes pharmacologically acceptable salts, solvates (especially hydrates) etc.

Exemplary proton pump inhibitors are those as described in the following Patent applications and patents described and claimed are: DE-A-35 31 487, EP-A-0 005 129, EP-A-0 124 495, EP-A-0 166 287, EP-A 0 174 726, EP-A-0 184 322, EP-A-0 254 588, EP-A-0 261 478, EP-A-0 268 956, EP-A-0 434 999 and WO-A-9523149. Examples include those Compounds 2- [2- (N-isobutyl-N-methylamino) benzylsulfinyl] benzimidazole (INN: Leminoprazole), 2- (4-methoxy- 6,7,8,9-tetrahydro-5H-cyclohepta [b] pyridin-9-ylsulfinyl) -1H-benzimidazole (INN: nepaprazole), 2- (4- Methoxy-3-methyl-pyridin-2-ylmethylsulfinyl) 5-pyrrol-1-y-1H-benzimidazole (IY-81149), 5-methoxy-2 - [(4- methoxy-3,5-dimethyl-2-pyridinyl) methylsulfinyl] -1H-imidazo [4,5-b] pyridine (tenatoprazole), especially 5-methoxy-2 - [(4-methoxy-3,5-dimethyl-2-pyridinyl) methylsulfinyl] -1H-benzimidazole (INN: omeprazole), 5-methoxy-2 - [(S) - [(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl] -1H-benzimidazole (INN: Esomeprazole), 2- [3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridinyl) methylsulfinyl] -1H-benzimidazole (INN: Lansoprazole) and 2 - {[4- (3-methoxypropoxy) -3-methylpyridin-2-yl] methylsulfinyl} -1H-benzimidazole (INN: Rabeprazole) and in particular 5-difluoromethoxy-2 - [(3,4-dimethoxy-2-pyridinyl) methylsulfinyl] -1H-benzimidazole (INN: pantoprazole) and (-) - 5-difluoromethoxy-2 - [(3,4-dimethoxy-2- pyridinyl) methylsulfinyl] - 1H-benzimidazole [(-) - pantoprazole].

The proton pump inhibitors exist as such or in the form of their salts with bases. Sodium, potassium, magnesium or calcium salts may be mentioned as examples of salts with bases. If the proton pump inhibitors or their salts are isolated in crystalline form, the crystals can contain variable amounts of solvent. According to the invention, the term proton pump inhibitor therefore also stands for all solvates, in particular all hydrates of the proton pump inhibitors and their salts. Particularly preferred salts or hydrates of proton pump inhibitors are pantoprazole sodium sesquihydrate (= pantoprazole sodium × 1.5 H ₂ O), (-) - pantoprazole sodium sesquihydrate, pantoprazole magnesium dihydrate, omeprazole magnesium, omeprazole magnesium tetrahydrate, esomeprazole -Magnesium and Esomeprazole-Magnesium called tetrahydrate.

• - β₂-Adrenoceptor Agonisten (insbesondere solche selektiv wirkenden Substanzen, die nur eine geringe kardiale Wirkung haben und daher auch in der Therapie von Atemwegserkrankungen eingesetzt werden), wie beispielsweise
  4-Hydroxy-7-[2-[2-[3-(2-phenylethoxy)propoxy]ethylamino]ethyl]benzothiazol-2(3H)-on (AR- C68164AA),
  3-[2-(4-Hydroxy-2-oxo-2,3-dihydrobenzothiazol-7-yl)ethylamino]-N-[2-[2-(4-methylphenyl)ethoxy]ethyl]- propan-sulfonamid (AR-C89855AA),
  5-[2-[N-(Dimethylaminocarbonyl)-N-(1,1-dimethylethyl)-amino]-1-hydroxyethyl]-1,3-benzenediol (BAMBUTEROL),
  4-Methylbenzoesäure-4-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-1,2-phenylen-ester (BITOLTEROL),
  3-Brom-α-[(tert-butylamino)methyl]-5-isoxazol-methanol (BROXATEROL),
  [5-[2-[(1,1-Dimethylethyl)amino]-1-hydroxyethyl]-2-hydroxyphenyl]harnstoff (CARBUTEROL),
  4-[2-(6-Phenethylamino-hexylamino)-ethyl]-benzene-1,2-diol (DOPEXAMINE),
  N-(3,3-Diphenylpropyl)-α-methylcyclohexaneethyl-amine (DROPRENILAMINE),
  (+/-)-2'-Hydroxy-5'-[(RS)-1-hydroxy-2-[[(RS)-p-methoxy-α-methylphenethyl]amino]ethyl]formanilid (FORMOTEROL),
  (R)-α₁-[(tert-Butylamino)methyl]-4-hydroxy-m-xylol-α,α'-diol (LEVOSALBUTAMOL),
  4-Amino-3-chlor-α-[[(1,1-dimethylethyl)amino]-methyl]-5-(trifluormethyl)-benzenemethanol (MABUTEROL),
  (-)-(R)-2-(tert-Butylamino)-1-(2-chlor-4-hydroxyphenyl)-ethanol (MELUADRINE),
  (+/-)-5,6-Diisobutyryloxy-2-(methylamino)-1,2,3,4-tetrahydronaphthalin (NOLOMIROLE),
  (RS)-{6-[2-(tert-Butylamino)-1-hydroxyethyl]-3-hydroxy-2-pyridyl}-methanol (PIRBUTEROL),
  7-[3-[[2-(3,5-Dihydroxyphenyl)-2-hydroxyethyl]amino]-propyl]-3,7-dihydro-1,3-dimethyl-1H-purin-2,6- dion (REPROTEROL),
  α(1)-[[(1,1-Dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol (SALBUTAMOL),
  (+/-)-N-[2-Hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]-ethyl]-N-[6-(4-phenylbutoxy)hexyl]amine (SALMETEROL),
  4-Hydroxy-7-[2-[2-[3-(2-phenylethoxy)propylsulfonyl]-ethylamino]ethyl]-benzothiazol-2(3H)-on (SIBENADET),
  [R-(R*,R*)]-8-Hydroxy-5-[1-hydroxy-2-[2-(4-methoxyphenyl)-1-methyl-ethylamino]ethyl]-2(1H)-quinolin (TA-2005),
  5-[2-((1.1-Dimethylethyl)amino]-1-hydroxyethyl]-1,3-benzenediol (TERBUTALINE),
  5-Chlor-3-[4-(2-hydroxyethyl)-1-piperazinyl]carbonyl-methyl-2-benzothiazolinon (TIARAMIDE) und
  α-[(tert-Butylamino)methyl]-o-chlorbenzyl-alcohol (TULOBUTEROL);
• - Muscarinrezeptor-Antagonisten, wie beispielsweise
  endo-8-(2-Fluorethyl)-3-[(hydroxydiphenylacetyl)oxy]-8-methyl-8-azoniabicyclo[3.2.1]octan-bromid (FLUTROPIUM BROMIDE),
  3-(3-Hydroxy-2-phenyl-propanoyloxy)-8-isopropyl-8-methyl-8-azoniabicyclo[3.2.1]octan-bromid (IPRATROPIUM BROMIDE),
  (8r)-6β-7β-Epoxy-8-ethyl-3-α-hydroxy-1-αH-5-αH-tropanium-bromid (OXITROPIUM BROMIDE),
  (R)-3-Quinuclidinyl-(S)-β-hydroxy-α-[2-(R)-methylsulfinyl]-ethyl]hydratropat (REVATROPATE) und
  [7(S)-(1α,2β,4β,5α,7β)]-7-[2-Hydroxy-2,2-di(2-thienyl)-acetoxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0(2.4)]nonanbromid (TIOTROPIUM BROMIDE);
• - Theophyllin-verwandte Bronchodilatoren, wie beispielsweise
  3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dion/1,2-Ethanediamin (AMINOPHYLLINE),
  3,7-Dihydro-1,3-dimethyl-7-[(5-methyl-1,2,4-oxadiazol-3-yl)-methyl]-1H-purin-2,6-dion (CHINOIN-170),
  7-(2,3-Dihydroxypropyl)-1,2,3,6-tetrahydro-1,3-dimethyl-purin-2,6-dion (DIPROPHYLLINE),
  7-(1,3-Dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-1H-purin-2,6-dion (DOXOFYLLINE),
  [R-(R*,S*)]-3-[(2-Hydroxy-1-methyl-2-phenylethyl)amino]-1-(3-methoxy-phenyl)-1-propanon (OXYFEDRINE),
  3,7-Dimethyl-1-hexyl-1H,3H-purin-2,6-dion (PENTIFYLLINE),
  3,7-Dihydro-3,7-dimethyl-1-(5-oxohexyl)-1H-purin-2,6-dion (PENTOXIFYLLINE),
  3,7-Dihydro-3-methyl-1-(5-oxohexyl)-7-propyl-1H-purin-2,6-dion (PROPENTOFYLLINE),
  3,7-Dihydro-7-(2-hydroxypropyl)-1,3-dimethyl-1H-purin-2,6-dion (PROXYPHYLLINE) und
  3,7-Dihydro-1,3-dimethyl-1H-purin-2,6-dion (THEOPHYLLINE);
• - PDE3/4- und PDE4-Hemmer, wie beispielsweise die in den folgenden Patentanmeldungen und Patenten beispielhaft genannten Verbindungen:
  EP 0163965, EP 0389282, EP 0393500, EP 0435811, EP 0482302, EP 0499216, EP 0506194, EP 0510562, EP 0528922, EP 0553174, EP 0731099, WO 9319749, WO 9500516, WO 9501338, WO 9600218, WO 9603399, WO 9611690, WO 9636625, WO 9636626, WO 9723457, WO 9728131, WO 9735854, WO 9740032, WO 9743288, WO 9809946, WO 9807715, WO 9808841, WO 9821207, WO 9821208, WO 9821209, WO 9822453, WO 9831674, WO 9840382, WO 9855481, WO 9905111, WO 9905112, WO 9905113, WO 9931071, WO 9931090, WO 9947505, WO 9957115, WO 9957118, WO 9964414, WO 0001695, WO 0012501, WO 0042017, WO 0042018, WO 0042019, WO 0042020, WO 0042034, WO 0119818, WO 0130766, WO 0130777 und WO 0151470, insbesondere die Verbindungen
  (Z)-3-(3,5-Dichlor-4-pyridyl)-2-[4-(2-indanyloxy-5-methoxy-2-pyridyl]propenenitril,
  N-[9-Amino-4-oxo-1-phenyl-3,4,6,7-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-3(R)-yl]pyridin-3- carboxamid (CI-1044),
  3-(Benzyloxy)-1-(4-fluorbenzyl)-N-[3-(methylsulfonyl)-phenyl]-1H-indol-2-carboxamid,
  (1S-exo)-5-[3-(Bicyclo[2.2.1]hept-2-yloxy)-4-methoxy-phenyl]tetrahydro-2(1H)-pyrimidinon (ATIZORAM),
  N-(3,5-Dichlor-4-pyridinyl)-2-[1-(4-fluorbenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamid (AWD-12-281),
  β-[3-(Cyclopentyloxy)-4-methoxyphenyl]-1,3-dihydro-1,3-dioxo-2H-isoindol-2-propanamid (CDC-801),
  N-[9-Methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydropyrrolo-[3,2,1-jk][1,4]benzodiazepin-3(R)-yl]pyridin-4- carboxamid (CI-1018),
  cis-[4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-carbonsäure (CILOMILAST),
  8-Amino-1,3-bis(cyclopropylmethyl)xanthin (CIPAMFYLLINE),
  N-(2,5-Dichlor-3-pyridinyl)-8-methoxy-5-quinolin-carboxamid (D-4418),
  5-(3,5-di-tert-Butyl-4-hydroxy-benzylidene)-2-imino-thiazolidin-4-on (DARBUFELONE),
  2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-1-propanon (IBUDILAST),
  Methanesulfonsäure-2-(2,4-dichlorphenylcarbonyl)-3-ureidobenzofuran-6-yl ester (LIRIMILAST),
  (-)-(R)-5-(4-Methoxy-3-propoxyphenyl)-5-methyloxazolidin-2-on (MESOPRAM),
  (-)-cis-9-Ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-6-(4-diisopropylaminocarbonyl-phenyl)- benzo[c][1,6]naphthyridin (PUMAFENTRINE),
  3-(Cyclopropylmethoxy)-N-(3,5-dichlor-4-pyridyl)-4-(difluormethoxy)-benzamid (ROFLUMILAST) (RS)-4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidinon (ROLIPRAM),
  5,6-Diethoxybenzo[b]thiophen-2-carbonsäure (TIBENELAST),
  2,3,6,7-Tetrahydro-2-(mesitylimino)-9,10-dimethoxy-3-methyl-4H-pyrimido[6,1-a]isoquinolin-4-on (TREQUINSIN) und
  3-[[3-(Cyclopentyloxy)-4-methoxyphenyl]methyl]-N-ethyl-8-(1-methylethyl)-3H-purin-6-amin (V- 11294A);
• - Prostaglandin D₂-Antagonisten, wie beispielsweise
  (1R,2R,3S,5S)-7-[2-(5-Hydroxybenzothiophen-3-ylcarboxamido)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]- 5(Z)-heptensäure (S-5751);
• - Adenosin A₃-Antagonisten, wie beispielsweise
  2-Methyl-6-phenyl-4-(phenylethynyl)-1,4-dihydropyridin-3,5-dicarbonsäure-3-ethyl 5-(3-methylbenzyl)- ester (MRS-1328),
  6-Ethyl-5-(ethylsulfanylcarbonyl)-2-phenyl-4-propyl-pyridin-3-carbonsäure-propylester (MRS-1523),
  6-Ethyl-5-(ethylsulfanylcarbonyl)-2-phenyl-4-propylpyridin-3-carbonsäure-ethylester (MRS-1476),
  2-(3-Chlorphenyl)-4,6-diethyl-5-(propylsulfanylcarbonyl)-pyridin-3-carbonsäure-propylester (MRS- 1505),
  4-Ethyl-5-(ethylsulfanylcarbonyl)-2-phenyl-6-propylpyridin-3-carbonsäure-ethylester (MRS-1486) und
  cis-3-(5,6-Dimethyl-2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-cyclopentanol (CDS-90910);
• - Bradykinin B2 Antagonisten, wie beispielsweise
  D-Arginyl-L-arginyl-L-prolyl-L-(4-hydroxy)prolyl-glycyl-L-(2-thienyl)alanyl-L-seryl-D-(1,2,3,4- tetrahydroisoquinolin-3-ylcarbonyl)-(N-cyclohexyl)glycyl-L-arginin (CP-0597),
  (E)-N-[N-[3-(3-Brom-2-methylimidazo[1,2-a]pyridin-8-yloxymethyl)-2,4-dichlorphenyl]-N- methylcarbamoyl-methyl]-4-(N,N-dimethylcarbamoyl)cinnamamid (FR-167344),
  3-(6-Acetamido-3-pyridyl)-N-[N-[2,4-dichlor-3-(2-methyl-quinolin-8-yloxymethyl)phenyl]-N- methylcarbamoyl-methyl]-2(E)-propenamid (FR-173657),
  D-Arginyl-arginyl-prolyl-[4(R)-hydroxy]prolyl-glycyl-(2-thienyl)alanyl-seryl-[1,2,3,4-tetrahydroisoquinolin- 3(R)-ylcarbonyl]-[(3aS,7aS)-octahydroindol-2(S)-ylcarbonyl]-arginin (ICATIBANT),
  1-[4-(Aminoiminomethyl)benzoyl]-4-[[(2S)-1-[[2,4-dichlor-3-[[(2,4-dimethyl-8-quinolinyl)oxy]methyl]phenyl]sulfonyl]-2-pyrrolidinyl]carbonyl]-piperazin (LF-16.0335) und
  D-Arginyl-L-arginyl-L-prolyl-L-(trans-4-hydroxy)prolyl-glycyl-L-phenylalanyl-L-seryl-D-(trans-4- propoxy)prolyl-L-[(2α,3β,7β)octahydroindol-2-ylcarbonyl]-L-arginine (NPC-17731);
• - Leukotrien LTB₄-Antagonisten, wie beispielsweise
  N-(Ethoxycarbonyl)-4-[3-[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxymethyl]benzyloxy]benzenecarboximidamid (AMELUBANT),
  2-[3-[3-(5-Ethyl-4'-fluor-2-hydroxybiphenyl-4-yloxy)-propoxy]-2-propylphenoxy]benzoesäure (LY- 293111) und
  4-[5-(4-Amidinophenoxy)pentyloxy]-N,N-diisopropyl-3-methoxybenzamide (MOXILUBANT);
• - Cysteinyl-Leukotrien₁-Rezeptorantagonisten, wie beispielsweise
  9-[(4-Acetyl-3-hydroxy-2-n-propylphenoxy)methyl]-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-on (AS-35),
  (+)-4(S)-(4-Carboxyphenylthio)-7-[4-(4-phenoxybutoxy)-phenyl]-5(Z)-heptensäure (BAY-X-7195),
  (E)-4-[3-[2-(4-Cyclobutylthiazol-2-yl)vinyl]phenylamino]-2,2-diethyl-4-oxobutansäure (CINALUKAST),
  6-(2-Cyclohexylethyl)-[1,3,4]thiadiazolo[3,2-a]1,2,3-triazolo[4,5-d]pyrimidin-9(1H)-on (DS-4574),
  7-[(1R,2S)-10-(4-Acetyl-3-hydroxy-2-propylphenoxy)-1-hydroxy-1-(3-trifluormethylphenyl)deca- 3(E),5(Z)-dien-2-ylthio]-4-oxo-4H-1-benzopyran-2-carbonsäure (IRALUKAST),
  4-[6-Acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)-propoxy]-2-propylphenoxy]buttersäure (KCA- 757),
  4-[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propylsulfonyl]-gamma-oxobenzenebuttersäure (L-648051) (E)-2,2-Diethyl-3'-[2-[2-(4-isopropyl)thiazolyl)ethenyl]-succinanilinsäure (MCI-826),
  2-[1-[1(R)-[3-[2(E)-(7-Chlorquinolin-2-yl)vinyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propylsulfanylmethyl]-cyclopropyl]essigsäure (MONTELUKAST),
  8-[4-(4-Phenylbutoxy)benzamido]-2-(tetrazol-5-yl)-4H-1-benzopyran-4-on (PRANLUKAST),
  2(S)-Hydroxy-3(R)-(2-carboxyethylthio)-3-[2-(8-phenyloctyl)-phenyl]propionsäure (POBILUKAST),
  5-[2-[4-(Quinolin-2-yl)methoxyphenoxymethyl]benzyl]-tetrazol (RG-12525),
  5-[3-[3-(2-Quinolinylmethoxy)phenoxy]propyl]-1H-tetrazol (RG-7152),
  1,1,1-Trifluor-N-[3-(2-quinolinylmethoxy)phenyl]methan-sulfonamid (RITOLUKAST)
  (1S,2R)-5-[3-[2-(2-Carboxyethylthio)-1-hydroxy-pentadeca-3(E),5(Z)-dienyl]phenyl]-1H-tetrazol (SULUKAST),
  2'-Hydroxy-3'-propyl-4'-[4-(1H-tetrazol-5-yl)-butoxy]acetophenon (TOMELUKAST),
  5-[3-[2-(7-Chlorquinolin-2yl)vinyl]phenyl]-8-(dimethyl-carbamoyl)-4,6-dithiaoctansäure (VERLUKAST),
  [[5-[[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]essigsäure (YM-638),
  4-(5-Cyclopentyloxycarbonylamino-1-methylindol-3-yl-methyl)-3-methoxy-N-o-tolylsulfonylbenzamid (ZAFIRLUKAST) und
  1(R)-3-Methoxy-4-[1-methyl-5-[N-(2-methyl-4,4,4-trifluor-butyl)carbamoyl]indol-3-ylmethyl]-N-(2- methylphenyl-sulfonyl)benzamid (ZD-3523);
• - Leukotrien-Synthese Inhibitoren, wie beispielsweise
  (+)-N-[3-[5-(4-Fluorphenoxy)-2-furyl]-1(R)-methyl-2-propynyl]-N-hydroxyharnstoff (ABT-175),
  (R)-N-[3-[5-(4-Fluorbenzyl)thien-2-yl]-1-methyl-2-propynyl]-N-hydroxyharnstoff (ATRELEUTON),
  (R)-2-Cyclopentyl-2-[4-(quinolin-2-ylmethoxy)phenyl]essigsäure (BAY-X-1005),
  (-)-2(R)-Cycloheptyl-2-[4-(2-quinolylmethoxy)phenyl]-N-(methylsulfonyl)-acetamide (BAY-Y-1015),
  N-(3-Phenoxycinnamyl)acetohydroxamsäure (BWA-4C),
  (2S,5S)-trans-2-(4-Fluorphenoxymethyl)-5-(4-N-hydroxy-ureidyl-1-butynyl)-tetrahydrofuran (CMI-977),
  (+/-)-4-(p-Fluorbenzyl)-2-(hexahydro-1-phenethyl-1H-azepin-4-yl)-1(2H)-phthalazinon (FLEZELASTINE),
  1-[[5'-(3"-Methoxy-4"-ethoxycarbonyloxyphenyl)-2',4-pentadienoyl]-aminoethyl]-4-diphenylmethoxypiperidin (LINETASTINE),
  3-[1-(4-Chlorbenzyl)-3-(tert-butylthio)-5-isopropyl-indol-2-yl]-2,2-dimethylpropionsäure (MK-886),
  (S)-N-[2-Cyclohexyl-1(S)-(2-pyridyl)ethyl]-5-methyl-benzoxazol-2-amin (ONTAZOLAST),
  [4R-[4α(1E,3S* ),5β]-1,4,5,6-Tetrahydro-5-hydroxy-4-(3-hydroxy-1-octenyl)-1-phenylcyclopenta[b]pyrrole-2-pentansäure (PIRIPROST),
  4-Hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1H)-on (PIRODOMAST),
  N-[3-(6-Methyl-3-pyridyl)acryloxy]-4-(4-diphenylmethyl-1-piperazinyl)butylamin (TAGORIZINE),
  4,4-bis[4-(Quinolin-2-ylmethoxy)phenyl]pentansäure (VML-530),
  6-[3-Ffluor-5-(4-methoxytetrahydropyran-4-yl)phenoxy-methyl]-1-methylquinolin-2(1H)-on (ZD-2138) und
  (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyharnstoff (ZILEUTON);
• - Lipoxygenase-Hemmer, wie beispielsweise
  N-[3-[5-(4-Ffluorphenoxy)-2-furyl]-1-methyl-2-propynyl]-N-hydroxyharnstoff (A-78773),
  1-(6-Phenoxy-2H-1-benzopyran-3-ylmethyl)-1-hydroxyharnstoff (CGS-23885),
  2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinon (DOCEBENONE),
  4-[[(6-Hydroxy-4,5,7-trimethyl-2-benzothiazolyl)amino]-methyl]benzenesulfonamid (E-6080),
  N-[2-[4-(Diphenylmethoxy)piperidin-1-yl]ethyl]-3-hydroxy-5-(3-pyridyl-methoxy)naphthalin-2-carboxamid (NC-2000),
  2-[3-(1-Hydroxyhexyl)phenoxymethyl)quinolin (REV-5901A),
  [2-[3,5-Bis(tert-butyl)-4-hydroxyphenylthio]-1-methyl-propoxy]essigsäure (SC-45662),
  4-Hydroxy-7-(4-hydroxy-3,5-dimethoxycinnamoylamino)-1-methyl-3-octyloxy-2(1H)-quinolin (TA-270),
  3-[5-(4-Chlorphenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-N-hydroxy-N-methylpropionamid (TEPOXALIN),
  S-(+)-α-Methyl-6-(2-quinolinylmethoxy)-2-naphthalin-essigsäure (WY-50295) und
  (2S,4R)-5-[4-(4-Hydroxy-2-methyltetrahydropyran-4-yl)-thien-2-yl-sulfanyl]-1-methyl-2,3-dihydro-1H- indol-2-on (ZD-4407);
• - Hemmstoffe der Mediatoren-Freisetzung, wie beispielsweise
  N,N'-(2-Chlor-5-cyan-m-phenylene)bis[glycolamid]diacetatester (ACREOZAST),
  1-[4-[3-[4-[Bis(4-fluorphenyl)hydroxymethyl]-1-piperidin-yl]propoxy]-3-methoxyphenyl]ethanon (AHR- 5333B),
  8-Hexyloxy-3-(1H-tetrazol-5-yl)-2H-chromen-2-on (AL-136),
  2-Amino-7-isopropyl-5-oxo-5H-[1]benzopyrano[2,3-b]pyridin-3-carbonsäure (AMLEXANOX),
  4-(1H-Tetrazol-5-yl)-N-[4-(1H-tetrazol-5-yl)phenyl]benzamid (ANDOLAST),
  2-Ethoxyethyl N-[4-(3-methylisoxazol-5-yl)thiazol-2-yl]-oxamat (ASOBAMAST),
  3-[3-(Methylcarbamoyloxy)propyl]-1-propylquinoxalin-2(1H)-on (BAMAQUIMAST),
  4'-tert-Butylphenyl-trans-4-guanidinomethylcyclohexan-carboxylat (BATEBULAST),
  6-Butyryl-1-ethyl-4-hydroxy-7-methyl-2-oxo-1,2-dihydro-quinolin-3-carbonsäure (CGP-25875),
  5-Methoxy-3-isopropoxy-1-phenyl-N-(1H-tetrazol 5-yl)-1H-indol-2-carboxamid (CI-949),
  3-Isopropoxy-5-methoxy-N-(1H-tetrazol-5-yl)benzo[b]thiophen-2-carboxamid (CI-959),
  Diethyl 1,3-bis[2-(ethoxycarbonyl)-4-oxo-4H-benzo[b]pyran-5-yloxy]-2-propyl-L-lysinat (CROMOGLICATE LISETIL),
  5,5'-(2-Hydroxytrimethyiendioxy)bis(4-oxo-4H-1-benzopyran-2-carbonsäure) (CROMOGLYCINSÄURE),
  11-Oxo-11H-pyrido[2,1-b]quinazolin-2-carbonsäure (DOQUALAST),
  1-[2-[(2,6-Dimethyl-3-nitro-4-pyridyl)amino]ethyl]-4-(diphenylmethyl)-piperazin (ELBANIZINE),
  6-(1-Pyrrolidinyl)-N-(1H-tetrazol-5-yl)pyrazin-2-carboxamid (HSR-6071),
  2-(Ethoxymethyl)pteridin-4(3H)-on (LCB-2183),
  1,6-Dihydro-2-[2-(2-methylpropoxy)anilino]-6-oxo-5-pyrimidine-carbonsäure (MAR-99),
  4,6-Dioxo-1-ethyl-10-propyl-4H,6H-pyrano[3,2-g]quinolin-2,8-dicarbonsäure (NEDOCROMIL),
  3-(5-Methylfurfuryl)-2-(4-piperidylamino)-3H-imidazo[4,5-b]pyridin (NOBERASTINE),
  1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-2-benzimidazolinon (OXATOMIDE),
  9-Methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-on (PEMIROLAST),
  7-[3-[4-[(4-Chlorphenyl)methyl]-1-piperazinyl]propoxy]-3,4-dimethyl-2H-1-benzopyran-2-on (PICUMAST),
  9-[2-Oxo-2-(pyrrolidin-1-yl)ethyl]-2,4-bis(pyrrolidin-1-yl)-9H-pyrimido[4,5-b]indol (PNU-142731A) 2-Carbomethoxy-5-chlor-1,3-oxazolo[4,5-h]quinolin (QUAZOLAST),
  4-Oxo-1-phenoxy-N-1H-tetrazol-5-yl-4H-quinolizin-3-carboxamid (QUINOTOLAST),
  Isoamyl 5,6-dihydro-7,8-dimethyl-4,5-dioxo-4H-pyrano[3,2-c]quinolin-2-carboxylat (REPIRINAST),
  [2-[4-(3-Ethoxy-2-hydroxopropoxy)phenylcarbamoyl]-ethyl]dimethyl-sulfonium p-toluolesulfonat (SUPLATAST TOSILATE),
  6-Methyl-N-(1H-tetrazol-5-yl)-2-pyridin (TA-5707),
  Butyl N-[3-(1H-tetrazol-5-yl)phenyl]oxamat (TAZANOLAST),
  Ethyl 4-methoxyphenyl-4-thiazolyl-2-oxamat (TIOXAMAST) und
  N-Acetylaspartyl-glutaminsäure Magnesiumsalz (ZY-15106);
• - Tachykinin NK₁ Antagonisten, wie beispielsweise
  CP-122721,
  (3aS,4S,7aS)-4-(2-Methoxyphenyl)-2-[2(S)-(2-methoxy-phenyl)-propionyl]-7,7-diphenylperhydroisoindol-4-ol (DAPITANT),
  N-[3-(2-Pentylphenyl)propanoyl]-threonyl-N-methyl-2,3-dehydrotyrosyl-leucyl-D-phenylalanyl-allothreonyl-asparaginyl-serin C-1.7-O-3.1-lacton (FK-224) und
  1-[2-[3-(3,4-Dichlorphenyl)-1-[2-(3-isopropoxyphenyl)-acetyl]piperidin-3(S)-yl]ethyl]-4-phenyl-1- azoniabicyclo[2.2.2]octan chlorid (NALPITANTIUM CHLORIDE);
• - Tachykinin NK₂ Antagonisten, wie beispielsweise
  (S)-N-[4-(4-Acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorphenyl)-butyl]-N-methylbenzamid (SARE- DUTANT);
• - Thromboxan A₂ Antagonisten, wie beispielsweise
  4-[2-(4-Chlorbenzenesulfonylamino)ethyl]benzene-essigsäure (DALTROBAN),
  3-(1H-Imidazol-1-ylmethyl)-2-methyl-1H-indol-1-propionsäure (DAZMEGREL),
  (+)-(Z)-7-[3-Endo-(phenylsulfonylamino)bicyclo[2.2.1]hept-2-exo-yl]-heptensäure (DOMITROBAN),
  7-[2α,4α-(Dimethylmethano)-6-β-(2-cyclopentyl-2β-hydroxyacetamido)-1α-cyclohexyl]-5(Z)- heptensäure (ONO-3708) und
  3-(4-tert-Butylthiazol-2-ylmethoxy)-N-[5-[3-(4-chlorpheny-Isulfonyl)propyl]-2-(1H-tetrazol-5- ylmethoxy)phenyl]benzamid (YM-158);
• - Thromboxan Synthase Inhibitoren, wie beispielsweise
  2-(1-Imidazolylmethyl)-4,5-dihydrobenzo[b]thiophen-6-carbonsäure (MITRODAST),
  1-[3-[4-(Diphenylmethyl)piperazin-1-yl]propyl]-3-(imidazol-1-ylmethyl)-indol-6-carbonsäure (KY-234),
  (E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]-2-propensäure (OZAGREL) und
  4-[α-Hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoesäure (Y-20811);
• - α₄β₁-(VLA-4)-Antagonisten, wie beispielsweise
  3-(1,3-Benzodioxol-5-yl)-3-[N-[2-(4-hydroxyphenyl)acetyl]-D,L-leucyl-amino]propionsäure (BIO-1006),
  N-[[4-[[[(2-Methylphenyl)amino]carbonyl]amino]phenyl]-acetyl]-L-leucyl-L-a-aspartyl-L-valyl-L-proline (BIO-1211),
  N-[5,5-Dimethyl-3-(4-methylphenylsulfonyl)thiazolidin-4(R)-ylcarbonyl]-4-O-[3-(dimethylamino)propyl]- L-tyrosin (CT-747),
  N-(4-Methylphenylsulfonyl)-L-prolyl-L-phenylalanin (CT-757),
  N-(4-Methylphenylsulfonyl)-L-prolyl-4-(4-piperidinyl-carboxamido)-L-phenylalanin (CT-767),
  N-[3-Acetyl-4(S)-thiazolidinylcarbonyl]-L-[4-O-(2,6-dichlor-benzyl)]-tyrosin (CT-5219),
  1-Methyl-4-[N-methyl-N-(2-phenylacetyl)-L-leucyl-L-aspartyl-L-phenylalanyl]-piperazin (CY-9701),
  3-[N-(3,4-Dimethoxybenzyl)-N-[2-[2-[3-methoxy-4-[3-(2-methylphenyl)ureido]phenyl]acetamido]acetyl]amino]-propionsäure (IVL-745),
  3(R)-[1-[2-[4-[3-(2-Methylphenyl)ureido]phenyl]acetyl]-pyrrolidin-2(S)-ylcarboxamido]buttersäure (OMEPUPA-V),
  3(S)-(1,3-Benzodioxol-5-yl)-3-[3-[2-(benzylsulfanyl)-1(S)-(phenylsulfanyl-methyl)ethyl]ureido]-propionsäure (TBC-3342),
  3(S)-(1,3-Benzodioxol-5-yl)-3-[N3-[1(S)-[N,N-bis(2-thienylmethyl)-carbamoyl]pentyl]ureido]propionsäure (TBC-3486),
  N-[3(R)-Carboxy-2,2,3-trimethylcyclopent-1(S)-ylcarbonyl]-4-(2,6-dichlorbenzamido)-L-phenylalanin (TR-9109),
  2(S)-(2,6-Dichlorbenzamido)-3-(2',6'-dimethoxybiphenyl-4-yl)-propionsäure (TR-14035) und
  3-[4-(4-Carbamoylpiperidin-1-ylcarbonyloxy)phenyl]-2(S)-[4-methyl-2(S)-[2-(2methylphenoxy)acetamido]pentanamido]-propionsäure;
• - VCAM-Inhibitoren, wie beispielsweise
  4-(4-Bromphenoxy)thieno[2,3-c]pyridine-2-carboxamid (A-249377),
  4-(4-Bromphenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamid (A-277232),
  N-Methyl-4-[4-(trifluormethyl)phenoxy]thieno[2,3-c]pyridin-2-carboxamid (A-277249),
  1-[2-[2,3-Dichlor-4-[trans-2-[N-[3-(2-oxopyrrolidin-1-yl)propyl]carbamoyl]cyclopropyl]phenylsulfanyl]phenyl]-piperidin-3-carbonsäure (A-324920),
  5(R)-(4-Brombenzyl)-3-(3,5-dichlorphenyl)-1,5-dimethylimidazolidin-2,4-dion (BIRT-377) und
  N-(Phenylsulfonyl)-4(S)-phenyl-L-prolyl-4-(2,6-dimethoxyphenyl)-L-phenylalanin (TR-14531), und
• - Chimase-Inhibitoren, wie beispielsweise
  (6R,7R)-7-Methoxy-7-[(2-methoxybenzoyl)amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5- oxa-1-azabicyclo[4.2.0]oct-2-en-2-carbonsäure-(3-carboxy-phenyl-methyl)ester (B-135),
  (6R,7R)-7-Methoxy-7-[(2-methoxybenzoyl)amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5- oxa-1-azabicyclo[4.2.0]oct-2-en-2-carbonsäure-(4-carboxy-phenyl-methyl)ester (B-136),
  (6R,7R)-7-Methoxy-7-[(2-methoxybenzoyl)amino]-8-oxo-3-[[[1-[2-oxo-2-(2-propenyloxy)ethyl]-1H- tetrazol-5-yl]thio]methyl]-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carbonsäure-(3-methylphenyl-methyl)- ester (B-146),
  (6R,7R)-3-[1-(Carboxymethyl)tetrazol-5-ylsulfanylmethyl]-7-methoxy-7-(2-methoxybenzamido)-1-oxa-3- cephem-4-carbonsäure-(3-methyl-benzyl)-ester (B-152) und
  (6R,7R)-3-[1-(Carboxymethyl)tetrazol-5-ylsulfanylmethyl]-7-methoxy-7-(2-ethoxybenzamido)-1-oxa-3- cephem-4-carbonsäure-(3-methyl-benzyl)-ester (B-153).

Active substances from various classes of active substances - with the exception of glucocorticoids - are suitable as respiratory therapeutic agents within the meaning of the invention, such as, for example, the following:

• β ₂ -adrenoceptor agonists (in particular those substances which act selectively and have only a slight cardiac effect and are therefore also used in the therapy of respiratory diseases), for example
  4-hydroxy-7- [2- [2- [3- (2-phenylethoxy) propoxy] ethylamino] ethyl] benzothiazol-2 (3H) -one (AR-C68164AA),
  3- [2- (4-Hydroxy-2-oxo-2,3-dihydrobenzothiazol-7-yl) ethylamino] -N- [2- [2- (4-methylphenyl) ethoxy] ethyl] propane sulfonamide (AR -C89855AA)
  5- [2- [N- (dimethylaminocarbonyl) -N- (1,1-dimethylethyl) amino] -1-hydroxyethyl] -1,3-benzenediol (BAMBUTEROL),
  4-methylbenzoic acid 4- [2 - [(1,1-dimethylethyl) amino] -1-hydroxyethyl] -1,2-phenylene ester (BITOLTEROL),
  3-bromo-α - [(tert-butylamino) methyl] -5-isoxazole-methanol (BROXATEROL),
  [5- [2 - [(1,1-dimethylethyl) amino] -1-hydroxyethyl] -2-hydroxyphenyl] urea (CARBUTEROL),
  4- [2- (6-phenethylamino-hexylamino) ethyl] benzene-1,2-diol (DOPEXAMINE),
  N- (3,3-diphenylpropyl) -α-methylcyclohexaneethyl-amine (DROPRENILAMINE),
  (+/-) - 2'-hydroxy-5 '- [(RS) -1-hydroxy-2 - [[(RS) -p-methoxy-α-methylphenethyl] amino] ethyl] formanilide (FORMOTEROL),
  (R) -α ₁ - [(tert-butylamino) methyl] -4-hydroxy-m-xylene-α, α'-diol (LEVOSALBUTAMOL),
  4-amino-3-chloro-α - [[(1,1-dimethylethyl) amino] methyl] -5- (trifluoromethyl) -benzenemethanol (MABUTEROL),
  (-) - (R) -2- (tert-butylamino) -1- (2-chloro-4-hydroxyphenyl) ethanol (MELUADRINE),
  (+/-) - 5,6-diisobutyryloxy-2- (methylamino) -1,2,3,4-tetrahydronaphthalene (NOLOMIROLE),
  (RS) - {6- [2- (tert-butylamino) -1-hydroxyethyl] -3-hydroxy-2-pyridyl} methanol (PIRBUTEROL),
  7- [3 - [[2- (3,5-Dihydroxyphenyl) -2-hydroxyethyl] amino] propyl] -3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (REPROTEROL )
  α (1) - [[(1,1-dimethylethyl) amino] methyl] -4-hydroxy-1,3-benzenedimethanol (SALBUTAMOL),
  (+/-) - N- [2-hydroxy-2- [4-hydroxy-3- (hydroxymethyl) phenyl] ethyl] -N- [6- (4-phenylbutoxy) hexyl] amine (SALMETEROL),
  4-hydroxy-7- [2- [2- [3- (2-phenylethoxy) propylsulfonyl] ethylamino] ethyl] benzothiazol-2 (3H) -one (SIBENADET),
  [R- (R *, R *)] - 8-hydroxy-5- [1-hydroxy-2- [2- (4-methoxyphenyl) -1-methyl-ethylamino] ethyl] -2 (1H) -quinoline ( TA-2005)
  5- [2 - ((1,1-dimethylethyl) amino] -1-hydroxyethyl] -1,3-benzenediol (TERBUTALINE),
  5-chloro-3- [4- (2-hydroxyethyl) -1-piperazinyl] carbonyl-methyl-2-benzothiazolinone (TIARAMIDE) and
  α - [(tert-Butylamino) methyl] -o-chlorobenzyl alcohol (TULOBUTEROL);
• Muscarinic receptor antagonists, such as
  endo-8- (2-fluoroethyl) -3 - [(hydroxydiphenylacetyl) oxy] -8-methyl-8-azoniabicyclo [3.2.1] octane bromide (FLUTROPIUM BROMIDE),
  3- (3-hydroxy-2-phenyl-propanoyloxy) -8-isopropyl-8-methyl-8-azoniabicyclo [3.2.1] octane bromide (IPRATROPIUM BROMIDE),
  (8r) -6β-7β-epoxy-8-ethyl-3-α-hydroxy-1-αH-5-αH-tropanium-bromide (OXITROPIUM BROMIDE),
  (R) -3-Quinuclidinyl- (S) -β-hydroxy-α- [2- (R) -methylsulfinyl] -ethyl] hydratropate (REVATROPATE) and
  [7 (S) - (1α, 2β, 4β, 5α, 7β)] - 7- [2-hydroxy-2,2-di (2-thienyl) acetoxy] -9,9-dimethyl-3-oxa- 9-azoniatricyclo [3.3.1.0 (2.4)] nonanbromide (TIOTROPIUM BROMIDE);
• - Theophylline-related bronchodilators, such as
  3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione / 1,2-ethanediamine (AMINOPHYLLINE),
  3,7-dihydro-1,3-dimethyl-7 - [(5-methyl-1,2,4-oxadiazol-3-yl) methyl] -1H-purine-2,6-dione (CHINOIN-170) .
  7- (2,3-dihydroxypropyl) -1,2,3,6-tetrahydro-1,3-dimethyl-purine-2,6-dione (DIPROPHYLLINE),
  7- (1,3-dioxolan-2-ylmethyl) -3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (DOXOFYLLINE),
  [R- (R *, S *)] - 3 - [(2-hydroxy-1-methyl-2-phenylethyl) amino] -1- (3-methoxyphenyl) -1-propanone (OXYFEDRINE),
  3,7-dimethyl-1-hexyl-1H, 3H-purine-2,6-dione (PENTIFYLLINE),
  3,7-dihydro-3,7-dimethyl-1- (5-oxohexyl) -1H-purine-2,6-dione (PENTOXIFYLLINE),
  3,7-dihydro-3-methyl-1- (5-oxohexyl) -7-propyl-1H-purine-2,6-dione (PROPENTOFYLLINE),
  3,7-dihydro-7- (2-hydroxypropyl) -1,3-dimethyl-1H-purine-2,6-dione (PROXYPHYLLINE) and
  3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (THEOPHYLLINE);
• PDE3 / 4 and PDE4 inhibitors, such as, for example, the compounds mentioned in the following patent applications and patents:
  EP 0163965, EP 0389282, EP 0393500, EP 0435811, EP 0482302, EP 0499216, EP 0506194, EP 0510562, EP 0528922, EP 0553174, EP 0731099, WO 9319749, WO 9500516, WO 9501338, WO 9600218, WO 96606 , WO 9636625, WO 9636626, WO 9723457, WO 9728131, WO 9735854, WO 9740032, WO 9743288, WO 9809946, WO 9807715, WO 9808841, WO 9821207, WO 9821208, WO 9821209, WO 9822453, WO 9831674, WO 9840382, WO 9840382, WO 9840382, WO 9840382, 9855481, WO 9905111, WO 9905112, WO 9905113, WO 9931071, WO 9931090, WO 9947505, WO 9957115, WO 9957118, WO 9964414, WO 0001695, WO 0012501, WO 0042017, WO 0042018, WO 0042019, WO 0042034, WO 0042034, WO 0119818, WO 0130766, WO 0130777 and WO 0151470, in particular the compounds
  (Z) -3- (3,5-dichloro-4-pyridyl) -2- [4- (2-indanyloxy-5-methoxy-2-pyridyl] propenenitril,
  N- [9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydropyrrolo [3,2,1-jk] [1,4] benzodiazepin-3 (R) -yl] pyridine-3 carboxamide (CI-1044),
  3- (benzyloxy) -1- (4-fluorobenzyl) -N- [3- (methylsulfonyl) phenyl] -1H-indole-2-carboxamide,
  (1S-exo) -5- [3- (bicyclo [2.2.1] hept-2-yloxy) -4-methoxyphenyl] tetrahydro-2 (1H) pyrimidinone (ATIZORAM),
  N- (3,5-dichloro-4-pyridinyl) -2- [1- (4-fluorobenzyl) -5-hydroxy-1H-indol-3-yl] -2-oxoacetamide (AWD-12-281),
  β- [3- (cyclopentyloxy) -4-methoxyphenyl] -1,3-dihydro-1,3-dioxo-2H-isoindole-2-propanamide (CDC-801),
  N- [9-methyl-4-oxo-1-phenyl-3,4,6,7-tetrahydropyrrolo [3,2,1-jk] [1,4] benzodiazepin-3 (R) -yl] pyridine 4-carboxamide (CI-1018),
  cis- [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1-carboxylic acid (CILOMILAST),
  8-amino-1,3-bis (cyclopropylmethyl) xanthine (CIPAMFYLLINE),
  N- (2,5-dichloro-3-pyridinyl) -8-methoxy-5-quinoline-carboxamide (D-4418),
  5- (3,5-di-tert-butyl-4-hydroxy-benzylidenes) -2-imino-thiazolidin-4-one (DARBUFELONE),
  2-methyl-1- [2- (1-methylethyl) pyrazolo [1,5-a] pyridin-3-yl] -1-propanone (IBUDILAST),
  Methanesulfonic acid 2- (2,4-dichlorophenylcarbonyl) -3-ureidobenzofuran-6-yl ester (LIRIMILAST),
  (-) - (R) -5- (4-methoxy-3-propoxyphenyl) -5-methyloxazolidin-2-one (MESOPRAM),
  (-) - cis-9-ethoxy-8-methoxy-2-methyl-1,2,3,4,4a, 10b-hexahydro-6- (4-diisopropylaminocarbonylphenyl) benzo [c] [1.6 ] naphthyridine (PUMAFENTRINE),
  3- (Cyclopropylmethoxy) -N- (3,5-dichloro-4-pyridyl) -4- (difluoromethoxy) benzamide (ROFLUMILAST) (RS) -4- (3-Cyclopentyloxy-4-methoxyphenyl) -2-pyrrolidinone ( ROLIPRAM)
  5,6-diethoxybenzo [b] thiophene-2-carboxylic acid (TIBENELAST),
  2,3,6,7-tetrahydro-2- (mesitylimino) -9,10-dimethoxy-3-methyl-4H-pyrimido [6,1-a] isoquinolin-4-one (TREQUINSIN) and
  3 - [[3- (Cyclopentyloxy) -4-methoxyphenyl] methyl] -N-ethyl-8- (1-methylethyl) -3H-purine-6-amine (V-11294A);
• - Prostaglandin D ₂ antagonists, such as
  (1R, 2R, 3S, 5S) -7- [2- (5-Hydroxybenzothiophene-3-ylcarboxamido) -6,6-dimethylbicyclo [3.1.1] hept-3-yl] - 5 (Z) -heptenic acid (S -5751);
• - adenosine A ₃ antagonists such as
  2-methyl-6-phenyl-4- (phenylethynyl) -1,4-dihydropyridine-3,5-dicarboxylic acid 3-ethyl 5- (3-methylbenzyl) ester (MRS-1328),
  Propyl 6-ethyl-5- (ethylsulfanylcarbonyl) -2-phenyl-4-propyl-pyridine-3-carboxylate (MRS-1523),
  6-ethyl-5- (ethylsulfanylcarbonyl) -2-phenyl-4-propylpyridine-3-carboxylic acid ethyl ester (MRS-1476),
  Propyl 2- (3-chlorophenyl) -4,6-diethyl-5- (propylsulfanylcarbonyl) pyridine-3-carboxylate (MRS-1505),
  4-ethyl-5- (ethylsulfanylcarbonyl) -2-phenyl-6-propylpyridine-3-carboxylic acid ethyl ester (MRS-1486) and
  cis-3- (5,6-dimethyl-2-phenyl-7H-pyrrolo [2,3-d] pyrimidin-4-ylamino) cyclopentanol (CDS-90910);
• Bradykinin B2 antagonists, such as
  D-Arginyl-L-arginyl-L-prolyl-L- (4-hydroxy) prolyl-glycyl-L- (2-thienyl) alanyl-L-seryl-D- (1,2,3,4-tetrahydroisoquinoline-3 -ylcarbonyl) - (N-cyclohexyl) glycyl-L-arginine (CP-0597),
  (E) -N- [N- [3- (3-bromo-2-methylimidazo [1,2-a] pyridin-8-yloxymethyl) -2,4-dichlorophenyl] -N-methylcarbamoyl-methyl] -4- (N, N-dimethylcarbamoyl) cinnamamide (FR-167344),
  3- (6-Acetamido-3-pyridyl) -N- [N- [2,4-dichloro-3- (2-methyl-quinolin-8-yloxymethyl) phenyl] -N-methylcarbamoyl-methyl] -2 (E. ) -propenamide (FR-173657),
  D-Arginyl-arginyl-prolyl- [4 (R) -hydroxy] prolyl-glycyl- (2-thienyl) alanyl-seryl- [1,2,3,4-tetrahydroisoquinoline-3 (R) -ylcarbonyl] - [( 3aS, 7aS) -octahydroindole-2 (S) -ylcarbonyl] -arginine (ICATIBANT),
  1- [4- (aminoiminomethyl) benzoyl] -4 - [[(2S) -1 - [[2,4-dichloro-3 - [[(2,4-dimethyl-8-quinolinyl) oxy] methyl] phenyl] sulfonyl] -2-pyrrolidinyl] carbonyl] piperazine (LF-16.0335) and
  D-Arginyl-L-arginyl-L-prolyl-L- (trans-4-hydroxy) prolyl-glycyl-L-phenylalanyl-L-seryl-D- (trans-4-propoxy) prolyl-L - [(2α, 3β, 7β) octahydroindol-2-ylcarbonyl] -L-arginine (NPC-17731);
• - Leukotriene LTB ₄ antagonists, such as
  N- (ethoxycarbonyl) -4- [3- [4- [1- (4-hydroxyphenyl) -1-methyl-ethyl] phenoxymethyl] benzyloxy] benzenecarboximidamide (AMELUBANT),
  2- [3- [3- (5-Ethyl-4'-fluoro-2-hydroxybiphenyl-4-yloxy) propoxy] -2-propylphenoxy] benzoic acid (LY-293111) and
  4- [5- (4-amidinophenoxy) pentyloxy] -N, N-diisopropyl-3-methoxybenzamide (MOXILUBANT);
• - Cysteinyl-leukotriene ₁ receptor antagonists, such as, for example
  9 - [(4-Acetyl-3-hydroxy-2-n-propylphenoxy) methyl] -3- (1H-tetrazol-5-yl) -4H-pyrido [1,2-a] pyrimidin-4-one (AS -35)
  (+) - 4 (S) - (4-carboxyphenylthio) -7- [4- (4-phenoxybutoxy) phenyl] -5 (Z) -heptenic acid (BAY-X-7195),
  (E) -4- [3- [2- (4-cyclobutylthiazol-2-yl) vinyl] phenylamino] -2,2-diethyl-4-oxobutanoic acid (CINALUKAST),
  6- (2-Cyclohexylethyl) - [1,3,4] thiadiazolo [3,2-a] 1,2,3-triazolo [4,5-d] pyrimidin-9 (1H) -one (DS-4574) .
  7 - [(1R, 2S) -10- (4-acetyl-3-hydroxy-2-propylphenoxy) -1-hydroxy-1- (3-trifluoromethylphenyl) deca- 3 (E), 5 (Z) -diene- 2-ylthio] -4-oxo-4H-1-benzopyran-2-carboxylic acid (IRALUKAST),
  4- [6-acetyl-3- [3- (4-acetyl-3-hydroxy-2-propylphenylthio) propoxy] -2-propylphenoxy] butyric acid (KCA-757),
  4- [3- (4-Acetyl-3-hydroxy-2-propylphenoxy) propylsulfonyl] gamma-oxobenzenebutyric acid (L-648051) (E) -2,2-diethyl-3 '- [2- [2- (4th -isopropyl) thiazolyl) ethenyl] -succinanilinic acid (MCI-826),
  2- [1- [1 (R) - [3- [2 (E) - (7-Chlorquinolin-2-yl) vinyl] phenyl] -3- [2- (1-hydroxy-1-methylethyl) phenyl] propylsulfanylmethyl] cyclopropyl] acetic acid (MONTELUKAST),
  8- [4- (4-phenylbutoxy) benzamido] -2- (tetrazol-5-yl) -4H-1-benzopyran-4-one (PRANLUKAST),
  2 (S) -hydroxy-3 (R) - (2-carboxyethylthio) -3- [2- (8-phenyloctyl) phenyl] propionic acid (POBILUKAST),
  5- [2- [4- (Quinolin-2-yl) methoxyphenoxymethyl] benzyl] tetrazole (RG-12525),
  5- [3- [3- (2-Quinolinylmethoxy) phenoxy] propyl] -1H-tetrazole (RG-7152),
  1,1,1-trifluoro-N- [3- (2-quinolinylmethoxy) phenyl] methanesulfonamide (RITOLUKAST)
  (1S, 2R) -5- [3- [2- (2-carboxyethylthio) -1-hydroxy-pentadeca-3 (E), 5 (Z) -dienyl] phenyl] -1H-tetrazole (SULUKAST),
  2'-hydroxy-3'-propyl-4 '- [4- (1H-tetrazol-5-yl) butoxy] acetophenone (TOMELUKAST),
  5- [3- [2- (7-chloroquinolin-2yl) vinyl] phenyl] -8- (dimethyl-carbamoyl) -4,6-dithiaoctanoic acid (VERLUKAST),
  [[5 - [[3- (4-Acetyl-3-hydroxy-2-propylphenoxy) propyl] thio] -1,3,4-thiadiazol-2-yl] thio] acetic acid (YM-638),
  4- (5-cyclopentyloxycarbonylamino-1-methylindol-3-ylmethyl) -3-methoxy-no-tolylsulfonylbenzamide (ZAFIRLUKAST) and
  1 (R) -3-methoxy-4- [1-methyl-5- [N- (2-methyl-4,4,4-trifluoro-butyl) carbamoyl] indol-3-ylmethyl] -N- (2- methylphenyl sulfonyl) benzamide (ZD-3523);
• - Leukotriene synthesis inhibitors, such as
  (+) - N- [3- [5- (4-fluorophenoxy) -2-furyl] -1 (R) -methyl-2-propynyl] -N-hydroxyurea (ABT-175),
  (R) -N- [3- [5- (4-fluorobenzyl) thien-2-yl] -1-methyl-2-propynyl] -N-hydroxyurea (ATRELEUTON),
  (R) -2-cyclopentyl-2- [4- (quinolin-2-ylmethoxy) phenyl] acetic acid (BAY-X-1005),
  (-) - 2 (R) -cycloheptyl-2- [4- (2-quinolylmethoxy) phenyl] -N- (methylsulfonyl) -acetamide (BAY-Y-1015),
  N- (3-phenoxycinnamyl) acetohydroxamic acid (BWA-4C),
  (2S, 5S) -trans-2- (4-fluorophenoxymethyl) -5- (4-N-hydroxy-ureidyl-1-butynyl) tetrahydrofuran (CMI-977),
  (+/-) - 4- (p-fluorobenzyl) -2- (hexahydro-1-phenethyl-1H-azepin-4-yl) -1 (2H) -phthalazinone (FLEZELASTINE),
  1 - [[5 '- (3 "-Methoxy-4" -ethoxycarbonyloxyphenyl) -2', 4-pentadienoyl] aminoethyl] -4-diphenylmethoxypiperidine (LINETASTINE),
  3- [1- (4-chlorobenzyl) -3- (tert-butylthio) -5-isopropylindol-2-yl] -2,2-dimethylpropionic acid (MK-886),
  (S) -N- [2-cyclohexyl-1 (S) - (2-pyridyl) ethyl] -5-methyl-benzoxazol-2-amine (ONTAZOLAST),
  [4R- [4α (1E, 3S *), 5β] -1,4,5,6-tetrahydro-5-hydroxy-4- (3-hydroxy-1-octenyl) -1-phenylcyclopenta [b] pyrrole-2 -pentanoic acid (PIRIPROST),
  4-hydroxy-1-phenyl-3- (1-pyrrolidinyl) -1,8-naphthyridin-2 (1H) -one (PIRODOMAST),
  N- [3- (6-methyl-3-pyridyl) acryloxy] -4- (4-diphenylmethyl-1-piperazinyl) butylamine (TAGORIZINE),
  4,4-bis [4- (quinolin-2-ylmethoxy) phenyl] pentanoic acid (VML-530),
  6- [3-fluoro-5- (4-methoxytetrahydropyran-4-yl) phenoxymethyl] -1-methylquinolin-2 (1H) -one (ZD-2138) and
  (+/-) - 1- (1-benzo [b] thien-2-ylethyl) -1-hydroxyurea (ZILEUTON);
• - Lipoxygenase inhibitors, such as
  N- [3- [5- (4-fluorophenoxy) -2-furyl] -1-methyl-2-propynyl] -N-hydroxyurea (A-78773),
  1- (6-phenoxy-2H-1-benzopyran-3-ylmethyl) -1-hydroxyurea (CGS-23885),
  2,3,5-trimethyl-6- (12-hydroxy-5,10-dodecadiynyl) -1,4-benzoquinone (DOCEBENONE),
  4 - [[(6-hydroxy-4,5,7-trimethyl-2-benzothiazolyl) amino] methyl] benzene sulfonamide (E-6080),
  N- [2- [4- (diphenylmethoxy) piperidin-1-yl] ethyl] -3-hydroxy-5- (3-pyridyl-methoxy) naphthalene-2-carboxamide (NC-2000),
  2- [3- (1-hydroxyhexyl) phenoxymethyl) quinoline (REV-5901A),
  [2- [3,5-bis (tert-butyl) -4-hydroxyphenylthio] -1-methyl-propoxy] acetic acid (SC-45662),
  4-hydroxy-7- (4-hydroxy-3,5-dimethoxycinnamoylamino) -1-methyl-3-octyloxy-2 (1H) -quinoline (TA-270),
  3- [5- (4-chlorophenyl) -1- (4-methoxyphenyl) pyrazol-3-yl] -N-hydroxy-N-methylpropionamide (TEPOXALIN),
  S - (+) - α-methyl-6- (2-quinolinylmethoxy) -2-naphthalene-acetic acid (WY-50295) and
  (2S, 4R) -5- [4- (4-Hydroxy-2-methyltetrahydropyran-4-yl) thien-2-yl-sulfanyl] -1-methyl-2,3-dihydro-1H-indole-2- on (ZD-4407);
• Mediator release inhibitors, such as
  N, N '- (2-chloro-5-cyan-m-phenylene) bis [glycolamide] diacetate ester (ACREOZAST),
  1- [4- [3- [4- [bis (4-fluorophenyl) hydroxymethyl] -1-piperidin-yl] propoxy] -3-methoxyphenyl] ethanone (AHR-5333B),
  8-hexyloxy-3- (1H-tetrazol-5-yl) -2H-chromen-2-one (AL-136),
  2-amino-7-isopropyl-5-oxo-5H- [1] benzopyrano [2,3-b] pyridine-3-carboxylic acid (AMLEXANOX),
  4- (1H-tetrazol-5-yl) -N- [4- (1H-tetrazol-5-yl) phenyl] benzamide (ANDOLAST),
  2-ethoxyethyl N- [4- (3-methylisoxazol-5-yl) thiazol-2-yl] oxamate (ASOBAMAST),
  3- [3- (methylcarbamoyloxy) propyl] -1-propylquinoxalin-2 (1H) -one (BAMAQUIMAST),
  4'-tert-butylphenyl-trans-4-guanidinomethylcyclohexane carboxylate (BATEBULAST),
  6-butyryl-1-ethyl-4-hydroxy-7-methyl-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid (CGP-25875),
  5-methoxy-3-isopropoxy-1-phenyl-N- (1H-tetrazol 5-yl) -1H-indole-2-carboxamide (CI-949),
  3-isopropoxy-5-methoxy-N- (1H-tetrazol-5-yl) benzo [b] thiophene-2-carboxamide (CI-959),
  Diethyl 1,3-bis [2- (ethoxycarbonyl) -4-oxo-4H-benzo [b] pyran-5-yloxy] -2-propyl-L-lysinate (CROMOGLICATE LISETIL),
  5,5 '- (2-Hydroxytrimethyiendioxy) bis (4-oxo-4H-1-benzopyran-2-carboxylic acid) (CROMOGLYCINIC ACID),
  11-oxo-11H-pyrido [2,1-b] quinazoline-2-carboxylic acid (DOQUALAST),
  1- [2 - [(2,6-dimethyl-3-nitro-4-pyridyl) amino] ethyl] -4- (diphenylmethyl) piperazine (ELBANIZINE),
  6- (1-pyrrolidinyl) -N- (1H-tetrazol-5-yl) pyrazine-2-carboxamide (HSR-6071),
  2- (ethoxymethyl) pteridin-4 (3H) -one (LCB-2183),
  1,6-dihydro-2- [2- (2-methylpropoxy) anilino] -6-oxo-5-pyrimidinecarboxylic acid (MAR-99),
  4,6-dioxo-1-ethyl-10-propyl-4H, 6H-pyrano [3,2-g] quinolin-2,8-dicarboxylic acid (NEDOCROMIL),
  3- (5-methylfurfuryl) -2- (4-piperidylamino) -3H-imidazo [4,5-b] pyridine (NOBERASTINE),
  1- [3- [4- (Diphenylmethyl) -1-piperazinyl] propyl] -2-benzimidazolinone (OXATOMIDE),
  9-methyl-3- (1H-tetrazol-5-yl) -4H-pyrido [1,2-a] pyrimidin-4-one (PEMIROLAST),
  7- [3- [4 - [(4-chlorophenyl) methyl] -1-piperazinyl] propoxy] -3,4-dimethyl-2H-1-benzopyran-2-one (PICUMAST),
  9- [2-Oxo-2- (pyrrolidin-1-yl) ethyl] -2,4-bis (pyrrolidin-1-yl) -9H-pyrimido [4,5-b] indole (PNU-142731A) 2- Carbomethoxy-5-chloro-1,3-oxazolo [4,5-h] quinoline (QUAZOLAST),
  4-oxo-1-phenoxy-N-1H-tetrazol-5-yl-4H-quinolizine-3-carboxamide (QUINOTOLAST),
  Isoamyl 5,6-dihydro-7,8-dimethyl-4,5-dioxo-4H-pyrano [3,2-c] quinoline-2-carboxylate (REPIRINAST),
  [2- [4- (3-ethoxy-2-hydroxopropoxy) phenylcarbamoyl] ethyl] dimethyl sulfonium p-toluenesulfonate (SUPLATAST TOSILATE),
  6-methyl-N- (1H-tetrazol-5-yl) -2-pyridine (TA-5707),
  Butyl N- [3- (1H-tetrazol-5-yl) phenyl] oxamate (TAZANOLAST),
  Ethyl 4-methoxyphenyl-4-thiazolyl-2-oxamate (TIOXAMAST) and
  N-acetylaspartyl glutamic acid magnesium salt (ZY-15106);
• - Tachykinin NK ₁ antagonists, such as
  CP-122721,
  (3aS, 4S, 7aS) -4- (2-methoxyphenyl) -2- [2 (S) - (2-methoxyphenyl) propionyl] -7,7-diphenylperhydroisoindol-4-ol (DAPITANT),
  N- [3- (2-pentylphenyl) propanoyl] threonyl-N-methyl-2,3-dehydrotyrosyl-leucyl-D-phenylalanyl-allothreonyl-asparaginyl-serine C-1.7-O-3.1-lactone (FK-224) and
  1- [2- [3- (3,4-dichlorophenyl) -1- [2- (3-isopropoxyphenyl) acetyl] piperidine-3 (S) -yl] ethyl] -4-phenyl-1-azoniabicyclo [2.2 .2] octane chloride (NALPITANTIUM CHLORIDE);
• - Tachykinin NK ₂ antagonists, such as
  (S) -N- [4- (4-acetamido-4-phenylpiperidin-1-yl) -2- (3,4-dichlorophenyl) butyl] -N-methylbenzamide (SARE-DUTANT);
• Thromboxane A ₂ antagonists, such as, for example
  4- [2- (4-chlorobenzenesulfonylamino) ethyl] benzene-acetic acid (DALTROBAN),
  3- (1H-imidazol-1-ylmethyl) -2-methyl-1H-indole-1-propionic acid (DAZMEGREL),
  (+) - (Z) -7- [3-endo- (phenylsulfonylamino) bicyclo [2.2.1] hept-2-exo-yl] -heptenic acid (DOMITROBAN),
  7- [2α, 4α- (Dimethylmethano) -6-β- (2-cyclopentyl-2β-hydroxyacetamido) -1α-cyclohexyl] -5 (Z) - heptenoic acid (ONO-3708) and
  3- (4-tert-Butylthiazol-2-ylmethoxy) -N- [5- [3- (4-chlorophenyisulfonyl) propyl] -2- (1H-tetrazol-5-ylmethoxy) phenyl] benzamide (YM-158 );
• Thromboxane synthase inhibitors, such as
  2- (1-imidazolylmethyl) -4,5-dihydrobenzo [b] thiophene-6-carboxylic acid (MITRODAST),
  1- [3- [4- (Diphenylmethyl) piperazin-1-yl] propyl] -3- (imidazol-1-ylmethyl) indole-6-carboxylic acid (KY-234),
  (E) -3- [4- (1H-Imidazol-1-ylmethyl) phenyl] -2-propenoic acid (OZAGREL) and
  4- [α-hydroxy-5- (1-imidazolyl) -2-methylbenzyl] -3,5-dimethylbenzoic acid (Y-20811);
• α ₄ β ₁ (VLA-4) antagonists, such as
  3- (1,3-benzodioxol-5-yl) -3- [N- [2- (4-hydroxyphenyl) acetyl] -D, L-leucylamino] propionic acid (BIO-1006),
  N - [[4 - [[[(2-methylphenyl) amino] carbonyl] amino] phenyl] acetyl] -L-leucyl-La-aspartyl-L-valyl-L-proline (BIO-1211),
  N- [5,5-dimethyl-3- (4-methylphenylsulfonyl) thiazolidin-4 (R) -ylcarbonyl] -4-O- [3- (dimethylamino) propyl] - L-tyrosine (CT-747),
  N- (4-methylphenylsulfonyl) -L-prolyl-L-phenylalanine (CT-757),
  N- (4-methylphenylsulfonyl) -L-prolyl-4- (4-piperidinyl-carboxamido) -L-phenylalanine (CT-767),
  N- [3-acetyl-4 (S) -thiazolidinylcarbonyl] -L- [4-O- (2,6-dichlorobenzyl)] tyrosine (CT-5219),
  1-methyl-4- [N-methyl-N- (2-phenylacetyl) -L-leucyl-L-aspartyl-L-phenylalanyl] piperazine (CY-9701),
  3- [N- (3,4-Dimethoxybenzyl) -N- [2- [2- [3-methoxy-4- [3- (2-methylphenyl) ureido] phenyl] acetamido] acetyl] amino] propionic acid (IVL -745)
  3 (R) - [1- [2- [4- [3- (2-methylphenyl) ureido] phenyl] acetyl] pyrrolidin-2 (S) -ylcarboxamido] butyric acid (OMEPUPA-V),
  3 (S) - (1,3-Benzodioxol-5-yl) -3- [3- [2- (benzylsulfanyl) -1 (S) - (phenylsulfanyl-methyl) ethyl] ureido] propionic acid (TBC-3342) .
  3 (S) - (1,3-Benzodioxol-5-yl) -3- [N3- [1 (S) - [N, N-bis (2-thienylmethyl) carbamoyl] pentyl] ureido] propionic acid (TBC- 3486),
  N- [3 (R) -carboxy-2,2,3-trimethylcyclopent-1 (S) -ylcarbonyl] -4- (2,6-dichlorobenzamido) -L-phenylalanine (TR-9109),
  2 (S) - (2,6-dichlorobenzamido) -3- (2 ', 6'-dimethoxybiphenyl-4-yl) propionic acid (TR-14035) and
  3- [4- (4-carbamoylpiperidin-1-ylcarbonyloxy) phenyl] -2 (S) - [4-methyl-2 (S) - [2- (2methylphenoxy) acetamido] pentanamido] -propionic acid;
• VCAM inhibitors, such as
  4- (4-bromophenoxy) thieno [2,3-c] pyridine-2-carboxamide (A-249377),
  4- (4-bromophenoxy) -N-methylthieno [2,3-c] pyridine-2-carboxamide (A-277232),
  N-methyl-4- [4- (trifluoromethyl) phenoxy] thieno [2,3-c] pyridine-2-carboxamide (A-277249),
  1- [2- [2,3-dichloro-4- [trans-2- [N- [3- (2-oxopyrrolidin-1-yl) propyl] carbamoyl] cyclopropyl] phenylsulfanyl] -phenyl] -piperidine-3-carboxylic acid (A-324920),
  5 (R) - (4-bromobenzyl) -3- (3,5-dichlorophenyl) -1,5-dimethylimidazolidine-2,4-dione (BIRT-377) and
  N- (phenylsulfonyl) -4 (S) -phenyl-L-prolyl-4- (2,6-dimethoxyphenyl) -L-phenylalanine (TR-14531), and
• - Chimase inhibitors, such as
  (6R, 7R) -7-methoxy-7 - [(2-methoxybenzoyl) amino] -3 - [[(1-methyl-1H-tetrazol-5-yl) thio] methyl] -8-oxo-5-oxa -1-azabicyclo [4.2.0] oct-2-en-2-carboxylic acid (3-carboxy-phenyl-methyl) ester (B-135),
  (6R, 7R) -7-methoxy-7 - [(2-methoxybenzoyl) amino] -3 - [[(1-methyl-1H-tetrazol-5-yl) thio] methyl] -8-oxo-5-oxa -1-azabicyclo [4.2.0] oct-2-en-2-carboxylic acid (4-carboxy-phenyl-methyl) ester (B-136),
  (6R, 7R) -7-methoxy-7 - [(2-methoxybenzoyl) amino] -8-oxo-3 - [[[1- [2-oxo-2- (2-propenyloxy) ethyl] -1H-tetrazole -5-yl] thio] methyl] -5-oxa-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid (3-methylphenylmethyl) ester (B-146),
  (6R, 7R) -3- [1- (carboxymethyl) tetrazol-5-ylsulfanylmethyl] -7-methoxy-7- (2-methoxybenzamido) -1-oxa-3-cephem-4-carboxylic acid- (3-methyl- benzyl) ester (B-152) and
  (6R, 7R) -3- [1- (carboxymethyl) tetrazol-5-ylsulfanylmethyl] -7-methoxy-7- (2-ethoxybenzamido) -1-oxa-3-cephem-4-carboxylic acid- (3-methyl- benzyl) ester (B-153).

The respiratory therapeutic agents can be present as such or in chemically bound form. this includes it is understood that the active substances mentioned, for example, also in the form of their pharmacological compatible salts and / or as solvates (e.g. hydrates), and / or in the form of their N-oxides etc. can. Suitable pharmacologically acceptable salts are, in particular, water-soluble and water-insoluble acid addition salts with acids such as hydrochloric acid, Hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, Benzoic acid, 2- (4-hydroxybenzoyl) benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, Lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, Toluenesulfonic acid, methanesulfonic acid or 1-hydroxy-2-naphthoic acid, the acids in the Salt production - depending on whether it is a single or polybasic acid and depending on which salt is desired - in an equimolar or a different quantity ratio be used. Furthermore, the active compounds mentioned can also be used as pure enantiomers or as Enantiomeric mixtures are present in any mixing ratio.

• - aus der Klasse der β₂-Adrenoceptor Agonisten die Wirkstoffe
  BAMBUTEROL, BITOLTEROL, BROXATEROL, CARBUTEROL, DOPEXAMINE, DROPRENILAMINE, FORMOTEROL, LEVOSALBUTAMOL, MABUTEROL, PIRBUTEROL, REPROTEROL, SALBUTAMOL, SALMETEROL, TERBUTALINE, TIARAMIDE und TULOBUTEROL;
• - aus der Klasse der Muscarinrezeptor-Antagonisten die Wirkstoffe
  FLUTROPIUM BROMIDE, IPRATROPIUM BROMIDE, OXITROPIUM BROMIDE und TIOTROPIUM BROMIDE;
• - aus der Klasse der Theophyllin-verwandte Bronchodilatoren die Wirkstoffe
  AMINOPHYLLINE, DIPROPHYLLINE, DOXOFYLLINE, OXYFEDRINE, PENTIFYLLINE, PENTOXIFYLLINE, PROPENTOFYLLINE und PROXYPHYLLINE;
• - aus der Klasse der PDE3/4- und PDE4-Hemmer die Wirkstoffe
  (Z)-3-(3,5-Dichlor-4-pyridyl)-2-[4-(2-indanyloxy-5-methoxy-2-pyridyl]propenenitril,
  N-[9-Amino-4-oxo-1-phenyl-3,4,6,7-tetrahydropyrrolo[3,2,1-jk][1,4]benzodiazepin-3(R)-yl]pyridin-3- carboxamid (CI-1044),
  N-(3,5-Dichlor-4-pyridinyl)-2-[1-(4-fluorbenzyl)-5-hydroxy-1H-indol-3-yl]-2-oxoacetamid (AWD-12-281),
  cis-[4-Cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexan-1-carbonsäure (CILOMILAST),
  8-Amino-1,3-bis(cyclopropylmethyl)xanthin (CIPAMFYLLINE),
  2-Methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]-1-propanon (IBUDILAST),
  Methanesulfonsäure-2-(2,4-dichlorphenylcarbonyl)-3-ureidobenzofuran-6-yl ester (LIRIMILAST),
  (-)-cis-9-Ethoxy-8-methoxy-2-methyl-1,2,3,4,4a,10b-hexahydro-6-(4-diisopropylaminocarbonylphenyl)-benzo[c][1,6]naphthyridin (PUMAFENTRINE),
  3-(Cyclopropylmethoxy)-N-(3,5-dichlor-4-pyridyl)-4-(difluormethoxy)-benzamid (ROFLUMILAST) und
  3-[[3-(Cyclopentyloxy)-4-methoxyphenyl]methyl]-N-ethyl-8-(1-methylethyl)-3H-purin-6-amin (V- 11294A);
• - aus der Klasse der Cysteinyl-Leukotrien₁-Rezeptorantagonisten die Wirkstoffe
  2-[1-[1(R)-[3-[2(E)-(7-Chlorquinolin-2-yl)vinyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propylsulfanylmethyl]-cyclopropyl]essigsäure (MONTELUKAST),
  8-[4-(4-Phenylbutoxy)benzamido]-2-(tetrazol-5-yl)-4H-1-benzopyran-4-on (PRANLUKAST) und
  4-(5-Cyclopentyloxycarbonylamino-1-methylindol-3-yl-methyl)-3-methoxy-N-o-tolylsulfonylbenzamid (ZAFIRLUKAST),
• - aus der Klasse der Leukotrien-Synthese Inhibitoren der Wirkstoff
  (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyharnstoff (ZILEUTON);
• - aus der Klasse der Lipoxygenase-Hemmer der Wirkstoff
  3-[5-(4-Chlorphenyl)-1-(4-methoxyphenyl)pyrazol-3-yl]-N-hydroxy-N-methylpropionamid (TEPOXALIN),
• - aus der Klasse der Hemmstoffe der Mediatoren-Freisetzung die Wirkstoffe
  2-Amino-7-isopropyl-5-oxo-5H-[1]benzopyrano[2,3-b]pyridin-3-carbonsäure (AMLEXANOX),
  5,5'-(2-Hydroxytrimethylendioxy)bis(4-oxo-4H-1-benzopyran-2-carbonsäure) (CROMOGLYCINSÄURE),
  4,6-Dioxo-1-ethyl-10-propyl-4H,6H-pyrano[3,2-g]quinolin-2,8-dicarbonsäure (NEDOCROMIL),
  1-[3-[4-(Diphenylmethyl)-1-piperazinyl]propyl]-2-benzimidazolinon (OXATOMIDE),
  9-Methyl-3-(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-on (PEMIROLAST),
  Isoamyl 5,6-dihydro-7,8-dimethyl-4,5-dioxo-4H-pyrano[3,2-c]quinolin-2-carboxylat (REPIRINAST),
  [2-[4-(3-Ethoxy-2-hydroxopropoxy)phenylcarbamoyl]-ethyl]dimethyl-sulfonium p-toluolesulfonat (SUPLATAST TOSILATE) und
  Butyl N-[3-(1H-tetrazol-5-yl)phenyl]oxamat (TAZANOLAST),
• - aus der Klasse der Thromboxan A2 Antagonisten der Wirkstoff
  (+)-(Z)-7-[3-Endo-(phenylsulfonylamino)bicyclo[2.2.1]hept-2-exo-yl]-heptensäure (DOMITROBAN),
• - und aus der Klasse der Thromboxan Synthase Inhibitoren der Wirkstoff
  (E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]-2-propensäure (OZAGREL).

Airway therapeutic agents to be emphasized in the sense of the invention in a combined application with a proton pump inhibitor are in particular

• - the active substances from the class of the β ₂ -adrenoceptor agonists
  BAMBUTEROL, BITOLTEROL, BROXATEROL, CARBUTEROL, DOPEXAMINE, DROPRENILAMINE, FORMOTEROL, LEVOSALBUTAMOL, MABUTEROL, PIRBUTEROL, REPROTEROL, SALBUTAMOL, SALMETEROL, TERBUTALINE, TOBARUTEROL;
• - The active substances from the class of muscarinic receptor antagonists
  FLUTROPIUM BROMIDE, IPRATROPIUM BROMIDE, OXITROPIUM BROMIDE and TIOTROPIUM BROMIDE;
• - The active substances from the class of theophylline-related bronchodilators
  AMINOPHYLLINE, DIPROPHYLLINE, DOXOFYLLINE, OXYFEDRINE, PENTIFYLLINE, PENTOXIFYLLINE, PROPENTOFYLLINE and PROXYPHYLLINE;
• - The active substances from the class of PDE3 / 4 and PDE4 inhibitors
  (Z) -3- (3,5-dichloro-4-pyridyl) -2- [4- (2-indanyloxy-5-methoxy-2-pyridyl] propenenitril,
  N- [9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydropyrrolo [3,2,1-jk] [1,4] benzodiazepin-3 (R) -yl] pyridine-3 carboxamide (CI-1044),
  N- (3,5-dichloro-4-pyridinyl) -2- [1- (4-fluorobenzyl) -5-hydroxy-1H-indol-3-yl] -2-oxoacetamide (AWD-12-281),
  cis- [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1-carboxylic acid (CILOMILAST),
  8-amino-1,3-bis (cyclopropylmethyl) xanthine (CIPAMFYLLINE),
  2-methyl-1- [2- (1-methylethyl) pyrazolo [1,5-a] pyridin-3-yl] -1-propanone (IBUDILAST),
  Methanesulfonic acid 2- (2,4-dichlorophenylcarbonyl) -3-ureidobenzofuran-6-yl ester (LIRIMILAST),
  (-) - cis-9-Ethoxy-8-methoxy-2-methyl-1,2,3,4,4a, 10b-hexahydro-6- (4-diisopropylaminocarbonylphenyl) benzo [c] [1,6] naphthyridin (pumafentrine)
  3- (cyclopropylmethoxy) -N- (3,5-dichloro-4-pyridyl) -4- (difluoromethoxy) benzamide (ROFLUMILAST) and
  3 - [[3- (Cyclopentyloxy) -4-methoxyphenyl] methyl] -N-ethyl-8- (1-methylethyl) -3H-purine-6-amine (V-11294A);
• - The active substances from the class of cysteinyl-leukotriene ₁ receptor antagonists
  2- [1- [1 (R) - [3- [2 (E) - (7-Chlorquinolin-2-yl) vinyl] phenyl] -3- [2- (1-hydroxy-1-methylethyl) phenyl] propylsulfanylmethyl] cyclopropyl] acetic acid (MONTELUKAST),
  8- [4- (4-phenylbutoxy) benzamido] -2- (tetrazol-5-yl) -4H-1-benzopyran-4-one (PRANLUKAST) and
  4- (5-cyclopentyloxycarbonylamino-1-methylindol-3-yl-methyl) -3-methoxy-no-tolylsulfonylbenzamide (ZAFIRLUKAST),
• - From the class of leukotriene synthesis inhibitors the active ingredient
  (+/-) - 1- (1-benzo [b] thien-2-ylethyl) -1-hydroxyurea (ZILEUTON);
• - The active ingredient from the class of lipoxygenase inhibitors
  3- [5- (4-chlorophenyl) -1- (4-methoxyphenyl) pyrazol-3-yl] -N-hydroxy-N-methylpropionamide (TEPOXALIN),
• - the active substances from the class of inhibitors of mediator release
  2-amino-7-isopropyl-5-oxo-5H- [1] benzopyrano [2,3-b] pyridine-3-carboxylic acid (AMLEXANOX),
  5,5 '- (2-hydroxytrimethylene dioxy) bis (4-oxo-4H-1-benzopyran-2-carboxylic acid) (CROMOGLYCINIC ACID),
  4,6-dioxo-1-ethyl-10-propyl-4H, 6H-pyrano [3,2-g] quinolin-2,8-dicarboxylic acid (NEDOCROMIL),
  1- [3- [4- (Diphenylmethyl) -1-piperazinyl] propyl] -2-benzimidazolinone (OXATOMIDE),
  9-methyl-3- (1H-tetrazol-5-yl) -4H-pyrido [1,2-a] pyrimidin-4-one (PEMIROLAST),
  Isoamyl 5,6-dihydro-7,8-dimethyl-4,5-dioxo-4H-pyrano [3,2-c] quinoline-2-carboxylate (REPIRINAST),
  [2- [4- (3-ethoxy-2-hydroxopropoxy) phenylcarbamoyl] ethyl] dimethyl sulfonium p-toluenesulfonate (SUPLATAST TOSILATE) and
  Butyl N- [3- (1H-tetrazol-5-yl) phenyl] oxamate (TAZANOLAST),
• - from the class of thromboxane A2 antagonists, the active ingredient
  (+) - (Z) -7- [3-endo- (phenylsulfonylamino) bicyclo [2.2.1] hept-2-exo-yl] -heptenic acid (DOMITROBAN),
• - And from the class of thromboxane synthase inhibitors the active ingredient
  (E) -3- [4- (1H-Imidazol-1-ylmethyl) phenyl] -2-propenoic acid (OZAGREL).

The subject of the invention to be emphasized is the combined application of Proton pump inhibitors and respiratory therapies from the class of PDE3 / 4 and PDE4 inhibitors in the Treatment of respiratory diseases.

The subject of the invention which is to be particularly emphasized is the combined use of a Proton pump inhibitor selected from the group consisting of 2- [2- (N-isobutyl-N-methylamino) - benzylsulfinyl] benzimidazole (Leminoprazole), 2- (4-methoxy-6,7,8,9-tetrahydro-5H-cyclohepta [b] pyridine- 9-ylsulfinyl) -1H-benzimidazole (nepaprazole), 2- (4-methoxy-3-methyl-pyridin-2-ylmethylsulfinyl) 5-pyrrol-1- y-1H-benzimidazole (IY-81149), 5-methoxy-2 - [(4-methoxy-3,5-dimethyl-2-pyridinyl) methylsulfinyl] -1H- imidazo [4,5-b] pyridine (tenatoprazole), 5-methoxy-2 - [(4-methoxy-3,5-dimethyl-2-pyridinyl) methylsulfinyl] -1H-benzimidazole (omeprazole), 5-methoxy-2 - [(S) - [(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl] -1H-benzimidazole (esomeprazole), 2- [3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridinyl) methylsulfinyl] -1H-benzimidazole (lansoprazole), 2 - {[4- (3-methoxypropoxy) -3-methylpyridine-2 yl] methylsulfinyl} - 1H-benzimidazole (rabeprazole), 5-difluoromethoxy-2 - [(3,4-dimethoxy-2-pyridinyl) methylsulfinyl] - 1H-benzimidazole (pantoprazole) and (-) - 5-difluoromethoxy-2 - [(3,4-dimethoxy-2-pyridinyl) methylsulfinyl] - 1H-benzimidazole [(-) - pantoprazole] and an airway therapeutic agent from the class of PDE3 / 4- and PDE4 inhibitors selected from the group consisting of (Z) -3- (3,5-dichloro-4-pyridyl) -2- [4- (2- indanyloxy-5-methoxy-2-pyridyl] propenenitril, N- [9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydropyrrolo [3,2,1-jk] [1,4] benzodiazepin-3 (R) -yl] pyridine-3 -carboxamide (CI-1044), N- (3,5-dichloro-4-pyridinyl) -2- [1- (4-fluorobenzyl) -5-hydroxy-1H-indol-3-yl] -2-oxoacetamide (AWD-12-281), cis- [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1-carboxylic acid (CILOMILAST), 8-amino-1,3-bis (cyclopropylmethyl) xanthine (CIPAMFYLLINE), 2-methyl-1- [2- (1-methylethyl) pyrazolo [1,5-a] pyridin-3-yl] -1-propanone (IBUDILAST), methanesulfonic acid 2- (2,4-dichlorophenylcarbonyl) -3-ureidobenzofuran-6-yl ester (LIRIMILAST), (-) - cis-9-Ethoxy-8-methoxy-2-methyl-1,2,3,4,4a, 10b-hexahydro-6- (4-diisopropylaminocarbonyl-phenyl) -benzo [c] [1,6 ] naphthyridine (PUMAFENTRINE), 3- (cyclopropylmethoxy) -N- (3,5-dichloro-4- pyridyl) -4- (difluoromethoxy) benzamide (ROFLUMILAST) and 3 - [[3- (Cyclopentyloxy) -4-methoxyphenyl] methyl] -N-ethyl-8- (1-methylethyl) -3H-purine-6-amine (V-11294A) in the treatment of Respiratory diseases.

The preferred object of the invention is the combined use of a Proton pump inhibitor selected from the group consisting of 5-methoxy-2 - [(4-methoxy-3,5-dimethyl-2- pyridinyl) methylsulfinyl] -1H-benzimidazole (omeprazole), 5-methoxy-2 - [(S) - [(4-methoxy-3,5-dimethyl-2- pyridinyl) methyl] sulfinyl] -1H-benzimidazole (esomeprazole), 2- [3-methyl-4- (2,2,2-trifluoroethoxy) -2- pyridinyl) methylsulfinyl] -1H-benzimidazole (lansoprazole), 2 - {[4- (3-methoxypropoxy) -3-methylpyridine-2- yl] -methylsulfinyl} -1H-benzimidazole (rabeprazole) and 5-difluoromethoxy-2 - [(3,4-dimethoxy-2- pyridinyl) methylsulfinyl] -1H-benzimidazole (pantoprazole) and an airway therapeutic agent from the Class of PDE3 / 4 and PDE4 inhibitors selected from the group consisting of cis- [4-cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1-carboxylic acid (CILOMILAST), 2-methyl-1- [2- (1- methylethyl) pyrazolo [1,5-a] pyridin-3-yl] -1-propanone (IBUDILAST), (-) - cis-9-ethoxy-8-methoxy-2-methyl- 1,2,3,4,4a, 10b-hexahydro-6- (4-diisopropylaminocarbonyl-phenyl) -benzo [c] [1,6] naphthyridine (PUMAFENTRINE) and 3- (cyclopropylmethoxy) -N- (3,5-dichloro-4-pyridyl) -4- (difluoromethoxy) benzamide (ROFLUMILAST) in the treatment of respiratory diseases.

A particularly preferred object of the invention is the combined use of 5-difluoromethoxy-2 - [(3,4-dimethoxy-2-pyridinyl) methylsulfinyl] -1H-benzimidazole (pantoprazole) and 3- (Cyclopropylmethoxy) -N- (3,5-dichloro-4-pyridyl) -4- (difluoromethoxy) benzamide (ROFLUMILAST) during treatment of respiratory diseases.

Respiratory diseases are, in particular, allergenic and inflammatory-induced pulmonary diseases Abnormalities or bronchial diseases (e.g. bronchitis, including obstructive bronchitis COPD, spastic bronchitis, allergic bronchitis, allergic asthma, bronchial asthma, called nocturnal asthma attacks, pneumonitis and Luingen fibrosis), which are caused by the Combination according to the invention also in the sense of long-term therapy (if desired under the respective Adjustment of the dosage of the individual components to the current, for example seasonal due to fluctuations).

"Combined application" or "combination" in the sense of the present invention is thus too understand that the individual components at the same time in a known and familiar manner (in the form of a combination medicinal product), more or less at the same time (from separate Packaging units) or one after the other (directly one after the other or even at a longer time interval) can be administered.

For the purposes of the present invention, “application” is preferably oral administration understood both active ingredients. However, parenteral (e.g. intravenous) is also conceivable, for example Administration of the proton pump inhibitor and / or parenteral or topical application (especially in inhaled form) of the respiratory therapeutic. The respiratory therapy is used for inhalative application preferably administered in the form of an aerosol, the aerosol particles solid, liquid or mixed composition with a diameter of 0.5 to 10 µm, advantageously have from 2 to 6 microns.

The aerosol generation can be done, for example, by pressure-driven nozzle atomizers or Ultrasonic nebulizers, but advantageously through propellant-driven metering aerosols or propellant-free ones Micronized active ingredients from inhalation capsules are used.

Depending on the inhalation system used, the dosage forms contain not only the active ingredients the necessary auxiliaries, such as propellant gases (e.g. frigging with MDIs), surface-active substances, emulsifiers, stabilizers, preservatives, flavorings, fillers (e.g. lactose in powder inhalers) or, if necessary, other active ingredients.

For the purposes of inhalation, a variety of devices are available with which aerosols optimal particle size and using the most patient-friendly Inhalation technology can be applied. In addition to the use of attachments (spacers, expanders) and pear-shaped containers (e.g. Nebulator®, Volumatic®) and automatic spray actuation (Autohaler®) for MDIs, there are a number of, especially for powder inhalers technical solutions are available (e.g. Diskhaler®, Rotadisk®, Turbohaler® or in the European patent application EP 0 505 321 described inhaler) with which an optimal Drug application can be achieved.

The active ingredients are dosed in the order of magnitude customary for the individual dosing, whereby due to the mutually positively influencing and reinforcing individual effects respective doses in the combined administration of the active ingredients can be reduced compared to the norm can, or - with the usual dosage of the individual components - a surprisingly better one and longer lasting effectiveness is achieved.

The proton pump inhibitor is usually administered in a dose between 5 and 100, advantageously between 10 and 60, in particular between 20 and 40 mg, in a dosage once or, if necessary, twice a day. In the case of airway therapeutic agents, the dose customary for the person skilled in the art is administered, which can vary within a very wide range depending on the active ingredient class. For example, the β ₂ adrenoceptor agonist - depending on the active ingredient - is usually administered by inhalation in a dosage of, for example, 0.002 to 2.0 mg per day. With oral administration, the dosages for the PDE inhibitors - depending on the active ingredient - can vary within a wide range, whereby a dose of 1-2000 µg / kg body weight can be assumed as a framework. When the preferred PDE inhibitor roflumilast is applied, the dosage is in the range of 2-20 µg / kg body weight

The proton pump inhibitors or respiratory therapeutics to be administered orally are - if necessary together - according to methods known per se and familiar to the person skilled in the art for medicinal products formulated. The pharmacologically active compounds (= active substances) preferably in combination with suitable pharmaceutical auxiliaries or carriers in the form of Tablets, coated tablets, capsules, emulsions, suspensions or solutions are used, the Active ingredient content is advantageously between 0.1 and 95% and with the appropriate choice the auxiliaries and excipients are based on the active ingredient (s) and / or the desired one Precisely adapted galenical dosage form (e.g. a slow-release form or a enteric form) can be achieved. Which auxiliaries or carriers for the desired Drug formulations are suitable is known to the person skilled in the art on the basis of his specialist knowledge. Next Solvents, gelling agents, tablet excipients and other active substance carriers can for example Antioxidants, dispersants, emulsifiers, defoamers, flavor correctors, Preservatives, solubilizers, dyes or permeation promoters and complexing agents (e.g. Cyclodextrins) are used, the well-known for all dosage forms Sensitivity - especially against acids - of the proton pump inhibitor has to be considered.

In another aspect, the invention relates to the use of a Proton pump inhibitor in combination with an airway therapeutic for the treatment of patients suffering from a Suffering from respiratory disease.

Another object of the invention is a method for the treatment of respiratory diseases is to give an effective amount to a patient in need of such treatment a proton pump inhibitor administered together with an airway therapeutic.

Another object of the invention is the use of proton pump inhibitors and Respiratory therapeutic agents for the manufacture of combination medicinal products for the treatment of Respiratory diseases.

Another object of the invention is a pharmaceutical preparation for the treatment of Respiratory diseases that are considered a proton pump inhibitor and an airway therapeutic contains active ingredients.

Another object of the invention is a finished drug containing one Proton pump inhibitors and an airway therapeutic agent as active ingredients, which is an indication of this contains these active ingredients for the treatment of respiratory disease more or less at the same time or one after the other (directly one after the other or with a larger time interval) should be taken.

Another object of the invention is a finished drug containing one Proton pump inhibitor as an active ingredient that contains an indication that this Proton pump inhibitor for the treatment of a respiratory disease with an airway therapeutic more or less at the same time or in succession (directly in succession or with a larger one time interval) should be taken.

Another object of the invention is a finished drug containing an airway therapeutic as an active ingredient that contains an indication that this respiratory therapeutic is used Treatment of a respiratory illness with a proton pump inhibitor more or less at the same time or one after the other (directly one after the other or even at a greater time interval) to be taken.

Claims (10)

1. Medicament for the treatment of respiratory diseases, containing one Proton pump inhibitors and an airway therapeutic in a fixed or free combination. 2. Medicament according to claim 1, characterized in that it is a fixed oral Combination. 3. Procedure for the treatment of respiratory diseases which consists in giving one Patients in need of such treatment, an effective amount of a proton pump inhibitor administered together with an airway therapeutic. 4. Use of a proton pump inhibitor in combination with an airway therapeutic used to treat patients with respiratory problems. 5. Pharmaceutical preparation for the treatment of respiratory diseases, the one Contains proton pump inhibitors and an airway therapeutic agent as active ingredients. 6. Finished medicinal product containing a proton pump inhibitor and an airway therapeutic agent active substances, which contains an indication that these active substances are used to treat a Respiratory disease more or less simultaneously or one after the other (directly one after the other or also with a larger interval) should be taken. 7. Finished medicinal product containing a proton pump inhibitor as an active ingredient, the one Indicates that this proton pump inhibitor is used to treat respiratory disease with an airway therapeutic more or less simultaneously or successively (directly consecutively or with a longer time interval). 8. Finished medicinal product containing an airway therapeutic agent as an active ingredient, which is a clue insists that using this airway therapeutic to treat respiratory disease a proton pump inhibitor more or less simultaneously or one after the other (one after the other or even with a longer interval) should be taken. 9. Composition, method, use or preparation according to one of claims 1 to 8, characterized characterized in that the proton pump inhibitor is selected from the group consisting of 5-methoxy-2 - [(4-methoxy-3,5-dimethyl-2-pyridinyl) methylsulfinyl] -1H-benzimidazole (omeprazole), 5-methoxy-2 - [(S) - [(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl] -1H-benzimidazole (esomeprazole), 2- [3-methyl-4- (2,2,2-trifluoroethoxy) -2-pyridinyl) methylsulfinyl] -1H-benzimidazole (lansoprazole), 2 - {[4- (3- Methoxypropoxy) -3-methylpyridin-2-yl] methylsulfinyl} -1H-benzimidazole (rabeprazole) and 5-difluoromethoxy-2 - [(3,4-dimethoxy-2-pyridinyl) methylsulfinyl] -1H-benzimidazole (pantoprazole) and its salts. 10. Composition, method, use or preparation according to one of claims 1 to 8, characterized characterized that the respiratory therapeutic is selected from the group consisting of cis- [4-Cyano-4- (3-cyclopentyloxy-4-methoxyphenyl) cyclohexane-1-carboxylic acid (CILOMILAST), 2-methyl-1 - [2- (1-methylethyl) pyrazolo [1,5-a] pyridin-3-yl] -1-propanone (IBUDILAST), (-) - cis-9-ethoxy-8-methoxy-2- methyl-1,2,3,4,4a, 10b-hexahydro-6- (4-diisopropylaminocarbonyl-phenyl) -benzo [c] [1,6] naphthyridine (PUMAFENTRINE) and 3- (cyclopropylmethoxy) -N- (3,5-dichloro-4-pyridyl) -4- (difluoromethoxy) benzamide (ROFLUMILAST) and their salts.